Experience with TachoSil in obstetric and gynecologic surgery

Abstract

Objective To evaluate the feasibility and effectiveness of using TachoSil during obstetric and gynecologic surgery. Methods The retrospective cohort study, conducted at a French university hospital, included women who experienced perioperative bleeding requiring the use of TachoSil during 2007–2009. The following information was collected: patient age, indication for the use of TachoSil, need for a blood transfusion, type of surgery performed, postoperative course, and traceability of TachoSil. Results TachoSil was used in 84 women. The main indications for the surgical interventions requiring TachoSil were ovarian malignancy (n = 18), fibroma (n = 17), breast cancer (n = 11), and endometrial cancer (n = 10). In 16 women, TachoSil was applied to the uterine serosa, particularly after cesarean delivery or polymyomectomy; in 7 women, it was applied to the major vascular axis. Red cell packs were infused in 24 women during surgery (average 3 packs per woman). Three women required repeat surgery. The use of TachoSil was not recorded in the operative reports of 43 (51%) women. Conclusion The present findings confirm that the use of TachoSil in gynecologic and obstetric surgeries is effective and well tolerated. Measures to improve the traceability of TachoSil use are recommended.